Abstract:Background: Inflammatory bowel disease (IBD) involves complicated crosstalk between host immunity and the gut microbiome, whereas the mechanics of how they govern intestinal inflammation remain poorly understood. In this study, we investigated the contribution of environmental factors to shaping gut microbiota composition in colitis mice that were transgenic for human IL-37, a natural anti-inflammatory cytokine possessing pathogenic and protective functions related to microbiota alterations. Methods: Mice transgenic expressing human IL-37 (IL-37tg) were housed under conventional and specific pathogen-free (SPF) conditions to develop a mouse model of dextran sulfate sodium (DSS)-induced colitis. 16S ribosomal RNA sequencing was used for analyzing fecal microbial communities. The efficacy of microbiota in the development of colitis in IL-37tg mice was investigated after antibiotic treatment and fecal microbiota transplantation (FMT). The mechanism by which IL-37 worsened colitis was studied by evaluating intestinal epithelial barrier function, immune cell infiltration, the expression of diverse cytokines and chemokines, as well as activated signaling pathways. Results: We found that IL-37 overexpression aggravated DSS-induced colitis in conventional mice but protected against colitis in SPF mice. These conflicting results from IL-37tg colitis mice are ascribed to a dysbiosis of the gut microbiota in which detrimental bacteria increased in IL-37tg conventional mice. We further identified that the outcome of IL-37-caused colon inflammation is strongly related to intestinal epithelial barrier impairment caused by pathogenic bacteria, neutrophils, and NK cells recruitment in colon lamina propria and mesenteric lymph node to enhance inflammatory responses in IL-37tg conventional mice. Conclusions: The immunoregulatory properties of IL-37 are detrimental in the face of dysbiosis of the intestinal microbiota, which contributes to exacerbated IBD occurrences that are uncontrollable by the immune system, suggesting that depleting gut pathogenic bacteria or maintaining intestinal microbial and immune homeostasis could be a promising therapeutic strategy for IBD.

IL-18 maintains the homeostasis of mucosal immune system via inflammasome-independent but microbiota-dependent manner

Impact of intestinal flora changes on the intestinal mucosal immunity in laboratory mice

Il-22 Deficiency Alters Colonic Microbiota to Be Transmissible and Colitogenic

Interleukin-6 absence triggers intestinal microbiota dysbiosis and mucosal immunity in mice

The absence of interleukin 10 affects the morphology, differentiation, granule content and the production of cryptidin-4 in Paneth cells in mice

Homeostatic Defects in Interleukin 18-Deficient Mice Contribute to Protection Against the Lethal Effects of Endotoxin.

Altered Immune Responses And Susceptibility To Leishmania Major And Staphylococcus Aureus Infection In Il-18-Deficient Mice

W1155 IL-21 Receptor Signaling Enhances NK Cell Cytolytic Activity and Induces Proinflammatory Cytokine Production in Inflammatory Bowel Disease

Microbiota downregulates dendritic cell expression of miR-10a, which targets IL-12/IL-23p40.

IL-17A-dependent Gut Microbiota is Essential for Regulating Diet-Induced Disorders in Mice

Altered Immune Responses and Susceptibility to<i>Leishmania major</i>and<i>Staphylococcus aureus</i>Infection in IL-18-Deficient Mice

Genetic and commensal induction of IL-18 drive intestinal epithelial MHCII via IFNγ

IL-1 Receptor Contributes to the Maintenance of the Intestinal Barrier via IL-22 during Obesity and Metabolic Syndrome in Experimental Model

Transient Activation of Mucosal Effector Immune Responses by Resident Intestinal Bacteria in Normal Hosts is Regulated by Interleukin-10 Signalling

Microbiota down-regulates intestinal DC expression of miR-107 which targets IL-23p19 and IL-10RB (P3158)

IL-17/IL-17R axis elicits intestinal neutrophil migration, restrains gut dysbiosis and LPS translocation in high-fat diet-induced metabolic syndrome model.

Interleukin-37 exacerbates experimental colitis in an intestinal microbiome-dependent fashion

Downregulation of microRNA-107 in intestinal CD11c(+) myeloid cells in response to microbiota and proinflammatory cytokines increases IL-23p19 expression.

Blockade of IL-18 signaling downregulates homing of effector CD4+ T cells to the gut mucosa and provides protection from experimental IBD

Deficiency of IL-22-binding protein enhances the ability of the gut microbiota to protect against enteric pathogens.

Immunodeficiency Promotes Adaptive Alterations of Host Gut Microbiome: an Observational Metagenomic Study in Mice